Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Sarcoma 1

Conditions

Sarcoma 1341Glioblastoma 493Gliosarcoma 470Osteosarcoma 364Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 252Neoplasms 231Glioma 230Lymphoma 227Rhabdomyosarcoma 209Neuroblastoma 209Breast Neoplasms 205Sarcoma, Ewing 203Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 183Ovarian Neoplasms 177Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 169Lymphoma, Follicular 158Liposarcoma 144Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Endometrial Cancer × Sarcoma × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡